XenoGesis’ Global Head of Business Development, Dr Rachel Hemsley has joined the University of Oxford’s Medical Sciences Experts in Residence (ExIR) scheme.
The Experts in Residence programme is managed by the Medical Science Division’s Translational Research Office, Business Development & Partnering team and Oxford University Innovation. It aims to give Oxford’s research community access to world-leading expertise and advice across multiple industry sectors. Scientists can arrange meetings with experts to discuss their ideas and projects with no strings attached. This advice and support helps scientists develop the translational strategy for their projects and technologies.
In addition, the experts give seminars and workshops aimed at early-career scientists and graduate students, which aim to improve understanding of the realities of technological development and commercialisation.
Commenting on the appointment, Rachel said: “I am delighted to have joined the Medical Sciences Expert in Residence scheme at the University of Oxford in this voluntary advisory role. I look forward to bringing my expertise to innovative translational research projects and advising on technical, pre-clinical or commercial development plans. The ExIR scheme will add significant value to Oxford’s entrepreneurial ecosystem which will have a long-term impact in the UK and worldwide.”
Rachel joined XenoGesis in 2017 as Global Head of Business Development and has been instrumental in driving the growth of the business. Rachel previously worked at UCL Business plc and has a wealth of experience in early-stage technology development in the biopharma sector, securing investment funding, licensing early-stage healthcare technologies and setting up new companies.
This article was written by Medilink EM Member, XenoGesis Ltd.